Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bevacizumab in ovarian cancer: A critical review of phase III studies.
Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V, Tomao F. Rossi L, et al. Among authors: zaccarelli e. Oncotarget. 2017 Feb 14;8(7):12389-12405. doi: 10.18632/oncotarget.13310. Oncotarget. 2017. PMID: 27852039 Free PMC article. Review.
Angiogenesis and antiangiogenic agents in cervical cancer.
Tomao F, Papa A, Rossi L, Zaccarelli E, Caruso D, Zoratto F, Benedetti Panici P, Tomao S. Tomao F, et al. Among authors: zaccarelli e. Onco Targets Ther. 2014 Dec 3;7:2237-48. doi: 10.2147/OTT.S68286. eCollection 2014. Onco Targets Ther. 2014. PMID: 25506227 Free PMC article. Review.
Triple-negative breast cancer: new perspectives for targeted therapies.
Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L, Tomao S. Tomao F, et al. Among authors: zaccarelli e. Onco Targets Ther. 2015 Jan 16;8:177-93. doi: 10.2147/OTT.S67673. eCollection 2015. Onco Targets Ther. 2015. PMID: 25653541 Free PMC article. Review.
Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
Giordani E, Zoratto F, Strudel M, Papa A, Rossi L, Minozzi M, Caruso D, Zaccarelli E, Verrico M, Tomao S. Giordani E, et al. Among authors: zaccarelli e. Curr Cancer Drug Targets. 2016;16(2):175-85. doi: 10.2174/1568009615666150817120712. Curr Cancer Drug Targets. 2016. PMID: 26278713 Review.
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, Tognon G, Lissoni AA, Rubino D, Ferrero A, Farina G, Negri E, Pesenti Gritti A, Galli F, Biagioli E, Rulli E, Poli D, Gerardi C, Torri V, Fossati R, D'Incalci M. Colombo N, et al. Among authors: zaccarelli e. Br J Cancer. 2019 Oct;121(9):744-750. doi: 10.1038/s41416-019-0584-5. Epub 2019 Sep 20. Br J Cancer. 2019. PMID: 31537908 Free PMC article. Clinical Trial.
139 results